Beta Drugs Limited (BETA)
Statement of deviation(s) or variation(s) under Reg. 32
Statement of deviation or variation under Reg. 32 for quarter ended 30-Sep-2026
- No deviation or variation in use of proceeds from preferential issue of Rs 117.01 Cr
- Audit Committee reviewed and Board took on record on 22-Oct-2026
- Funds utilized as per original objects: facility upgrades, R&D setup, geographical expansion, capex, capital investment, corporate
- Total utilized Rs 47.37 Cr with no deviations reported
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 BETA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add BETA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Beta Drugs Limited
Important.
The summary above is generated automatically from Beta Drugs Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.